Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
STAAR Surgical Company Fourth Quarter 2025 Earnings Call - Inventory Reset and Swiss-Made EVO+ Position STAAR for 2026 Profitability
STAAR closed a turbulent 2025 with stabilized distributor inventories in China, a sharper cost base, and early commercial production from its Nidau, Switzerland facility aimed at EVO+ demand. Q4 net s...
- Interim leadership in place: Warren Foust and Deborah Andrews appointed Co-CEOs (interim) effective February 1, with Egon Zehnder engaged to search for a permanent CEO.
- Q4 top-line: total net sales $57.8M vs $49.0M a year ago; China net sales $17.5M (Q4 2024: $7.8M).
- Distributor inventory reset in China was deliberate: STAAR paused shipments to normalize channel inventory after elevated levels in 2024, including consumption of a $27.5M December 2024 China shipment during FY2025.
- +13 more takeaways
Ascent Industries Co. Q4 2025 Earnings Call - Structural shift to specialty chemicals drives ~1,000 bps gross margin expansion and $10M+ commercial win
Ascent closed 2025 as a leaner, debt-free specialty chemicals company after exiting legacy tubular assets and the Monell site, and it points to durable margin gains rather than cyclical luck. On a ful...
- Company repositioned into a pure-play specialty chemical platform, permanently exiting legacy tubular assets and the Monell facility.
- Full-year gross margin expanded nearly 1,000 basis points year-over-year, with gross profit up 61% for 2025.
- Adjusted EBITDA improved by about $4.1 million year-over-year for the full year, despite roughly 7% lower revenue versus prior year.
- +14 more takeaways
Cricut Q4 2025 Earnings Call - Profit Up, Revenue Flat as Cricut Bets Big on Bundles and AI
Cricut closed 2025 profitable and cash-generative, but topline momentum is missing. Full-year revenue slipped less than 1% to $708.8 million and Q4 sales fell 3% to $203.6 million, even as net income ...
- Revenue stalled, profits did not. Full-year revenue was $708.8 million, down under 1% year-over-year, while net income rose 22% to $76.7 million.
- Q4 soft patch. Q4 revenue was $203.6 million, down 3% year-over-year, with Q4 net income of $7.8 million, or $0.04 per diluted share.
- Platform is the engine. Platform revenue grew 5% for the year, paid subscribers rose to 3.09 million (up 132,000, +4%), and ARPU increased 5% to $55.77.
- +14 more takeaways
Latham Group, Inc. Q4 and Full Year 2025 Earnings Call - Fiberglass adoption drives outperformance and margin expansion
Latham closed 2025 by outpacing a weak U.S. in-ground pool market, driven by accelerating Fiberglass adoption, auto cover momentum, and margin gains from lean manufacturing and value engineering. Mana...
- Q4 2025 net sales were $100 million, up 15% year-over-year, with organic growth of 14% for the quarter.
- Full-year 2025 net sales were $546 million, up 7% versus $509 million in 2024, achieved while U.S. in-ground pool starts were estimated down low- to mid-single digits.
- Fiberglass pools now represent 76.5% of Latham’s in-ground pool sales in 2025, and Latham’s Fiberglass sales grew approximately 2.5% year-over-year.
- +17 more takeaways
Superior Group of Companies Q4 2025 Earnings Call - Back-end weighted growth, margin lift and AI-driven contact center pivot
Superior posted a muted top line but a noticeable bottom-line recovery in Q4 2025. Consolidated revenue was $147 million, up 1% year-over-year and up 6% sequentially, while EBITDA rose to $8.6 million...
- Consolidated revenue was $147.0 million in Q4 2025, up 1% year-over-year and up 6% sequentially, confirming management’s back-end weighted cadence thesis.
- EBITDA rose to $8.6 million from $7.3 million a year earlier, a 19% increase, and EBITDA margin expanded 90 basis points to 5.9%.
- Diluted EPS nearly doubled to $0.23 in Q4 2025, up from $0.13 in the year-ago quarter.
- +15 more takeaways
Cryoport Q4 & FY2025 Earnings Call - Spring-loaded clinical pipeline sets up commercial revenue surge
Cryoport closed 2025 with a clean beat and a forward-looking posture. Continuing-operations revenue was $176.2 million, above prior guidance, driven by a 29% jump in commercial cell and gene therapy r...
- Continuing-operations revenue for FY2025 was $176.2 million, above the high end of prior guidance.
- Full-year commercial cell and gene therapy revenue rose 29% year-over-year to a record $33.4 million, now representing about 20% of total revenue.
- Clinical trial revenue increased 14% year-over-year to $47.1 million; Cryoport supported a record 760 clinical trials and 20 commercial therapies at year end.
- +11 more takeaways
Evolus Q4 and Full Year 2025 Earnings Call - Portfolio Rebate and Evolysse Launch Set Stage for 2026 Profitability
Evolus closed 2025 with momentum and a clear pivot: double-digit top-line growth, tighter cost discipline, and an explicit plan to use a portfolio rebate and product rollouts to push accounts deeper i...
- Top-line and product mix: Q4 2025 global net revenue was $90.3 million, with full-year 2025 revenue of $297.2 million, up 12% year-over-year and marking six consecutive years of double-digit growth.
- Jeuveau strength: Jeuveau accounted for $83.1 million of Q4 revenue, and management says Jeuveau holds roughly 14% U.S. toxin market share, with continued unit share gains even in a soft procedural environment.
- Evolysse early traction: Evolysse generated $7.2 million in Q4 revenue, more than 3,000 purchasing accounts to date, and management plans a broader sampling and experience program in Q2 2026 to accelerate adoption.
- +13 more takeaways
Arcturus Therapeutics Q4 2025 Earnings Call - Kicking off a 12-week CF Phase 2 as OTC moves to Type C regulatory clarity
Arcturus is narrowing its focus and putting real weight behind two rare disease programs. The company will initiate a 12-week Phase 2 study of ARCT-032 for cystic fibrosis in H1 2026, starting the coh...
- Arcturus will initiate dosing for a 12-week Phase 2 study of ARCT-032 (CF mRNA therapeutic) in H1 2026, enrolling up to 20 Class 1 CF patients across U.S. and international sites.
- The fourth cohort will start at 10 mg with the protocol preserving flexibility to escalate to 15 mg if needed; safety and tolerability were observed at 15 mg in prior cohorts.
- Study design upgrades aim to tighten baseline stability and improve signal detection, including requiring reproducible baseline spirometry before enrollment.
- +11 more takeaways
B&G Foods Q4 Fiscal 2025 Earnings Call - Portfolio reshaping pivots out Green Giant frozen to fund higher-margin broths and simplify the company
B&G Foods used this quarter’s results to press the accelerator on portfolio reshaping, selling the Green Giant US frozen business to Seneca and signing to buy College Inn and Kitchen Basics broths fro...
- B&G closed the sale of Green Giant US Frozen to Seneca Foods, receiving approximately $63.2 million in proceeds, and retained a co-pack manufacturing arrangement in Irapuato, Mexico.
- The Green Giant US divestiture removes roughly $203 million of net sales year-over-year from the company, with Seneca co-pack volumes expected to generate about $80 million of revenue from March through fiscal year-end and roughly $100 million on an annualized run-rate, with modest profit for B&G.
- Green Giant Canada divestiture remains pending regulatory approval in Canada, expected to close in Q2 fiscal 2026; related impairments were recorded earlier in the year, including a $27.8 million pre-tax impairment in Q3 and $0.7 million in Q4 for assets held for sale.
- +11 more takeaways
Quantum-Si Q4 2025 Earnings Call - Announces $425,000 Proteus, pivots 2026 to a transition year focused on launch
Quantum-Si used this call to recast 2026 as a deliberate transition year, trading near-term instrument revenue for a concentrated push to launch Proteus at year-end. Management announced a $425,000 li...
- Company frames 2026 as a transition year, prioritizing Proteus development and market preparation over near-term Platinum Pro instrument sales.
- Proteus list price announced at $425,000, released early to enable customer budgeting and channel planning, but no secured orders disclosed.
- Revenue pressure persists: Q4 2025 revenue of $451,000, full-year 2025 revenue of $2.4 million, and management expects roughly $1 million in revenue for 2026.
- +12 more takeaways